MK-4409

MK-4409
Clinical data
ATC code	None;
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 2-[5-[5-(5-Chloropyridin-2-yl)sulfanyl-2-(4-fluorophenyl)-1,3-oxazol-4-yl]pyridin-2-yl]propan-2-ol;
CAS Number	1207745-58-1 ;
PubChem CID	53341130;
ChemSpider	25069631;
UNII	77GX6MU9ZL;
ChEMBL	ChEMBL1812717;
CompTox Dashboard (EPA)	DTXSID101045923 ;
Chemical and physical data
Formula	C22H17FN3O2S
Molar mass	406.46 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c3nc(C(O)(C)C)ccc3-c1nc(-c4ccc(F)cc4)oc1Sc(nc2)ccc2Cl;
	InChI InChI=1S/C22H17ClFN3O2S/c1-22(2,28)17-9-5-14(11-25-17)19-21(30-18-10-6-15(23)12-26-18)29-20(27-19)13-3-7-16(24)8-4-13/h3-12,28H,1-2H3; Key:DBZMCSVIITXLCC-UHFFFAOYSA-N;

MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC₅₀ of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was studied for the treatment of neuropathic pain and progressed to early stage human clinical trials by 2009.^[1]^[2]

References

^ Chobanian HR, Guo Y, Liu P, Chioda MD, Fung S, Lanza TJ, et al. (June 2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Medicinal Chemistry Letters. 5 (6): 717–21. doi:10.1021/ml5001239. PMC 4060928. PMID 24944750.
^ Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.